Clinical and Economic Outcomes of Treatment Sequences for Intermediate- To Poor-Risk Advanced Renal Cell Carcinoma

Immunotherapy - United Kingdom
doi 10.2217/imt-2019-0199
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Real-World Clinical Outcomes of Pazopanib Immediately Following Immunotherapy Discontinuation for the Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2020English

Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2015English

Puk9 - Network Meta-Analysis of Treatments in Previously Untreated Advanced or Metastatic Renal-Cell Carcinoma With Intermediate to Poor Prognosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice
Oncology
2019English

Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives

Cancer
Cancer ResearchOncology
2017English

Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need?

Current Urology Reports
MedicineUrology
2013English

Profile of Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2010English

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

M-Tor Inhibitors in the Treatment of Advanced Renal Cell Carcinoma

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy